We recently published a list of the Top 10 AI Stocks Buzzing on Latest News. In this article, we are going to take a look at ...

Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMTSalt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical ...

// Program to find the sum of the sequence of numbers using recursion.

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...

REC-1245 is Recursion’s first program to emerge from end-to-end use of Recursion OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in ...